ConductScience.org, home

Cell line · CVCL_4358

LL/2 (LLC1)

Cancer cell line, Mus musculus. Malignant tumors of the mouse pulmonary system. 135 papers.

4 sourcescell-lines-2026-11-14-0.1.0

Download JSON
Cite this record

ConductScience Library. LL/2 (LLC1). Cell lines, record CVCL_4358. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_4358

On this page

Cell line

As Cellosaurus gives it.

Name
LL/2 (LLC1)
Accession
CVCL_4358
RRID
RRID:CVCL_4358
Synonyms
LL/2 (LLc1), LL/2(LLc1), LL/2, LL2, LLC1, LLC, Lewis lung carcinoma line 1, Lewis lung carcinoma, Lewis Lung Cancer, Lewis-Lung, Lewis Lung
Species
Mus musculus (Mouse)
Category
Cancer cell line
Diseases
Malignant tumors of the mouse pulmonary system (NCIt C21769)
Derived from
Lung (in situ)
Entry created
2012-04-04
Entry updated
2026-06-25

Source Cellosaurus

Problems1

ProblemCellosaurus's note
CautionCould be identical to 3LL (Cellosaurus=CVCL_5653).

Papers135

1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.

PaperJournalYearHow we knowRetractedSource
PubMed 42999416Transl Lung Cancer Res2026Its Methods give the RRID and name the linePubMed
Integrated Computational Pipeline Combining Metabolomics and Network Pharmacology for Bioactive Scaffold Discovery: Application to Antarctic Moss Chorisodontium aciphyllum.Chem Biodivers2026Its Methods give the RRID and name the linePubMed
Blocking aryl hydrocarbon receptor remodels myeloid-T cell crosstalk and enhances anti-PD-1 response in the tumor microenvironment.Exp Hematol Oncol2026Its Methods give the RRID and name the linePubMed
Combined HER2-targeted mRNA-LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights.Bioeng Transl Med2026Its Methods give the RRID and name the linePubMed
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis.Mol Oncol2026Its Methods give the RRID and name the linePubMed
Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment.J Immunother Cancer2026Its Methods give the RRID and name the linePubMed
Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
HIF1A+CSF3R+ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC.J Immunother Cancer2026Its Methods give the RRID and name the linePubMed
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.J Exp Med2026Its Methods give the RRID and name the linePubMed

1 to 10 of 135

See all 135 papers

Relatives47

RelationCell lineAccessionProblemSource
Derived from itEDITGENE Kras (p.G12C) Point Mutation in LLC Cell LineCVCL_F5YJCell lines
Derived from itEDITGENE Kras, p.G12C & Trp53, p.R172H Point Mutation in LLC Cell LineCVCL_F5YKCell lines
Derived from itEDITGENE LLC-CopGFPCVCL_F6C8Cell lines
Derived from itEDITGENE LLC-FLUCCVCL_F5URCell lines
Derived from itEDITGENE Trp53 (p.R172H) Point Mutation in LLC Cell LineCVCL_F5YLCell lines
Derived from itGenomeditech LLC1 H_SLC39A6CVCL_E6W9Cell lines
Derived from itHyCyte LL/2 (LLC1) KO-mArg2CVCL_F1R8Cell lines
Derived from itHyCyte LL/2 (LLC1) KO-mChchd10CVCL_F4JICell lines
Derived from itHyCyte LL/2 (LLC1) KO-mIrf7CVCL_E1LRCell lines
Derived from itHyCyte LL/2 (LLC1) KO-mItgalCVCL_F1R9Cell lines

Cell banks16

Cell bankCatalog numberStatusSource
ATCCCRL-1642ATCC
AddexBioC0016030/5000Cellosaurus
BCRC60050BCRC
BCRJ0145BCRJ
CLS305311CLS
CLS400263DiscontinuedCellosaurus
ECACC90020104ECACC
EDITGENEEDC00260EDITGENE
HysigenTCM-C742Hysigen
IZSLERBS TCL 216Cellosaurus

Data dates

The date of each source this release read.

Cellosaurus
2026-10-22
Cellosaurus
PubMed Central's articles
2026-11-12
PubMed Central's articles
Our copy of PubMed
2026-11-06
Our copy of PubMed

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this cell line from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_4358

GET https://conductscience.org/api/cell-lines/v1/CVCL_4358/papers?page=2